Press release
-
Press Release
YY Group (NASDAQ: YYGH) Announces Strategic Partnership with Velobotics to Advance Autonomous Facility Management Capabilities in Southeast Asia
24-month partnership positions YY Group as a regional deployment partner for Velobotics’ VIGGO autonomous fleets in Singapore and Malaysia. Initiative…
Read More » -
Press Release
Applied Aerospace & Defense, Inc. Announces Launch of Initial Public Offering
HUNTSVILLE, Ala., May 26, 2026 /PRNewswire/ — Applied Aerospace & Defense, Inc., an advanced manufacturer of mission critical systems for…
Read More » -
Press Release
Applied Aerospace & Defense, Inc. Announces Launch of Initial Public Offering
HUNTSVILLE, Ala., May 26, 2026 /PRNewswire/ — Applied Aerospace & Defense, Inc., an advanced manufacturer of mission critical systems for…
Read More » -
Press Release
Cogent Communications Announces Definitive Agreement to Sell 10 Data Center Facilities
WASHINGTON, May 26, 2026 /PRNewswire/ — Cogent Communications Holdings, Inc. (“Cogent”) (NASDAQ: CCOI) today announced that its indirect wholly owned subsidiary,…
Read More » -
Press Release
Cogent Communications Announces Definitive Agreement to Sell 10 Data Center Facilities
WASHINGTON, May 26, 2026 /PRNewswire/ — Cogent Communications Holdings, Inc. (“Cogent”) (NASDAQ: CCOI) today announced that its indirect wholly owned subsidiary,…
Read More » -
Press Release
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a…
Read More » -
Press Release
Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a…
Read More » -
Press Release
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
LONDON, May 26, 2026 /PRNewswire/ — Virax Biolabs Group Limited (NASDAQ: VRAX) (“Virax” or the “Company”) today reported positive early…
Read More »
